CHEMED CORP
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.5B | $2.4B | $2.3B | $2.1B | $2.1B |
| Cost of revenue | $1.7B | $1.6B | $1.5B | $1.4B | $1.4B |
| Selling, general & administrative | $417.2M | $424.4M | $395.1M | $358.7M | $366.7M |
| Operating expenses | $2.2B | $2.1B | $1.9B | $1.8B | — |
| Operating income | $338.2M | $366.5M | $340.6M | $343.5M | $343.0M |
| Interest expense | $1.8M | $1.8M | $3.1M | $4.6M | $1.9M |
| Pretax income | $355.8M | $399.5M | $350.4M | $329.7M | $350.3M |
| Income tax expense | $90.5M | $97.5M | $77.9M | $80.1M | $81.8M |
| Net income | $265.2M | $302.0M | $272.5M | $249.6M | $268.6M |
| Balance Sheet | |||||
| Cash and equivalents | $74.5M | $178.3M | $264.0M | $74.1M | $32.9M |
| Current assets | $302.6M | $394.7M | $500.8M | $272.6M | $230.3M |
| Total assets | $1.5B | $1.7B | $1.7B | $1.4B | $1.3B |
| Current liabilities | $287.1M | $285.7M | $312.1M | $297.2M | $302.4M |
| Total liabilities | $558.8M | $549.6M | $560.2M | $643.3M | $719.5M |
| Stockholders' equity | $979.4M | $1.1B | $1.1B | $798.7M | $623.3M |
| Cash Flow Statement | |||||
| Cash from operations | $388.3M | $417.5M | $330.3M | $309.9M | $308.6M |
| Depreciation and amortization | $64.8M | $63.0M | $60.9M | $59.2M | $59.1M |
| Stock-based compensation | $38.7M | $52.1M | $40.8M | $33.6M | $31.4M |
| Capital expenditure | $62.8M | $49.5M | $56.9M | $57.3M | $58.7M |
| Free cash flow | $325.5M | $368.0M | $273.4M | $252.6M | $249.9M |
| Dividends paid | $31.7M | $27.1M | $23.5M | $22.0M | $22.0M |
| Share repurchases | $431.5M | $361.4M | $67.7M | $114.5M | $576.0M |
Shares outstanding 13.3M · Free float 95.1%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.